EPISODE · Dec 3, 2020 · 8 MIN
Andreas Hochhaus, MD, on Asciminib vs Bosutinib for Pretreated CML-CP
from Oncology Learning Network · host HMP Global
In this podcast, Andreas Hochhaus, MD, University Medical Center Jena, Germany, discusses the use of asciminib versus bosutinib for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP) previously given ≥2 tyrosine kinase inhibitors (TKIs). These data were presented at the virtual 2020 ASH Annual Meeting and Exposition.
Embed this episode
Ready to play
Andreas Hochhaus, MD, on Asciminib vs Bosutinib for Pretreated CML-CP
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.